Favipiravir

Generic Name: Favipiravir

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄FN_₃O_₂

CAS Number: 259793-96-9

Unique Ingredient Identifier: EW5GL2X7E0

Background: Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.

Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.

Indication: ⑴用于埃博拉病毒感染的治疗。

⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）

Associated Conditions: Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza

Clinical Trials

Favipiravir in Hospitalized COVID-19 Patients

Phase 4

Conditions: COVID-19

Interventions: Drug: Favipiravir
Drug: Hydroxychloroquine

First Posted Date: 2020-04-24

Last Posted Date: 2020-04-28

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT04359615

Locations: 🇮🇷
Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

Efficacy of Faviprevir in COVID-19 Treatment

Phase 2

Completed

Conditions: COVID

Interventions: Drug: Favipiravir
Drug: Chloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2021-11-01

Lead Sponsor: Tanta University

Target Recruit Count: 92

Registration Number: NCT04351295

Locations: 🇪🇬
Tanta University, Ainshams University, Tanta, Egypt

Efficacy and Safety of Favipiravir in Management of COVID-19

Phase 3

Completed

Conditions: Coronavirus Disease (COVID-19)

Interventions: Drug: Standard of care therapy
Drug: favipiravir

First Posted Date: 2020-04-16

Last Posted Date: 2020-06-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 100

Registration Number: NCT04349241

Locations: 🇪🇬
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

Phase 2

Completed

Conditions: COVID-19
Sars-CoV2

Interventions: Drug: Favipiravir
Drug: Placebo
Other: Standard of care treatment

First Posted Date: 2020-04-15

Last Posted Date: 2022-07-13

Lead Sponsor: Stanford University

Target Recruit Count: 149

Registration Number: NCT04346628

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

Phase 3

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Favipiravir

First Posted Date: 2020-04-07

Last Posted Date: 2020-04-08

Lead Sponsor: Giuliano Rizzardini

Target Recruit Count: 100

Registration Number: NCT04336904

Locations: 🇮🇹
Asst Fatebenefratelli Sacco, Milano, Italy

Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

Not Applicable

Conditions: COVID-19

Interventions: Drug: Favipiravir

First Posted Date: 2020-04-03

Last Posted Date: 2020-04-24

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 210

Registration Number: NCT04333589

Locations: 🇨🇳
Ezhou Central Hospital, Wuhan, Hubei, China
🇨🇳
Jinyintan Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳
Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China

and more 5 locations

Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia

Phase 2

Conditions: Novel Coronavirus Pnuemonia

Interventions: Drug: Favipiravir tablets
Drug: Placebo
Drug: favipiravir tablets+chloroquine phosphatetablets tablets

First Posted Date: 2020-03-24

Last Posted Date: 2020-03-24

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 150

Registration Number: NCT04319900

Locations: 🇨🇳
Beijing Chaoyang hospital, Beijing, Beijing, China

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

Not Applicable

Conditions: COVID-19

Interventions: Drug: Favipiravir Combined With Tocilizumab
Drug: Favipiravir
Drug: Tocilizumab

First Posted Date: 2020-03-17

Last Posted Date: 2020-04-10

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 150

Registration Number: NCT04310228

Locations: 🇨🇳
Guiqiang Wang, Beijing, Beijing, China
🇨🇳
Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳
Jinyintan Hospital of Wuhan, Wuhan, Hubei, China

and more 3 locations